Salivary Melatonin Profile: When to Order This Test

What a Salivary Melatonin Profile Actually Measures

A salivary melatonin profile quantifies the concentration of melatonin in saliva at multiple time points, generating a curve that reveals when melatonin secretion begins, peaks, and declines. The pineal gland synthesizes melatonin from serotonin under control of the suprachiasmatic nucleus (SCN), and roughly 70% of circulating melatonin diffuses passively into saliva [1]. That tight correlation makes saliva a reliable, non-invasive proxy for plasma levels.

The single most valuable data point from this curve is the DLMO. Defined as the time when salivary melatonin first exceeds a fixed threshold (commonly 3 pg/mL, though some labs use 4 pg/mL), the DLMO marks the physiological start of the biological night [2]. A 2003 study by Lewy and colleagues (N=29) demonstrated that DLMO correlated with circadian phase more reliably than core body temperature nadir or actigraphy-derived sleep onset, with an intraclass correlation coefficient of 0.89 across repeated measurements [3]. The American Academy of Sleep Medicine (AASM) has recognized DLMO as the most accurate marker of circadian timing available in clinical practice [4].

Saliva collection typically involves 7 to 12 samples taken every 30 to 60 minutes, starting about 5 to 6 hours before the patient's habitual bedtime. The patient must remain in dim light (below 30 lux, roughly equivalent to candlelight) throughout the collection window. Bright light suppresses melatonin acutely: a 2001 study in the Journal of Clinical Endocrinology & Metabolism showed that exposure to 500 lux for just 30 minutes delayed DLMO by an average of 36 minutes and reduced peak melatonin amplitude by 38% [5].

When Clinicians Should Order This Test

The short answer: order a salivary melatonin profile when you suspect a circadian rhythm sleep-wake disorder (CRSWD) and the clinical history alone cannot distinguish it from behavioral insomnia or another sleep pathology. The test moves from optional to necessary in several specific scenarios.

Delayed sleep-wake phase disorder (DSWPD). This is the most common indication. Patients present with an inability to fall asleep before 2:00-4:00 AM despite adequate sleep opportunity. The 2015 AASM clinical practice guidelines for CRSWD recommend DLMO assessment to confirm the diagnosis and guide the timing of chronotherapy, light therapy, or exogenous melatonin [4]. DSWPD prevalence reaches 7-16% in adolescents and young adults [6].

Advanced sleep-wake phase disorder (ASWPD). Less common, predominantly affecting older adults, ASWPD features sleep onset before 8:00 PM and final awakening before 4:00 AM. A salivary melatonin profile can confirm an abnormally early DLMO, typically occurring before 6:00 PM, separating ASWPD from depression-related early-morning awakening.

Non-24-hour sleep-wake rhythm disorder. Seen almost exclusively in totally blind individuals (prevalence of roughly 50-80% in this population), non-24-hour disorder produces a free-running circadian rhythm [7]. Serial DLMO measurements spaced 1 to 2 weeks apart can document the progressive daily drift of roughly 12 to 30 minutes that characterizes this condition.

Shift-work circadian adaptation. For night-shift workers experiencing persistent insomnia or excessive sleepiness, a DLMO measurement can reveal whether the circadian clock has shifted toward the desired schedule or remains locked to the solar day.

Pre-treatment baseline for timed melatonin therapy. The Endocrine Society and multiple sleep-medicine consensus panels note that exogenous melatonin works best when administered 4 to 6 hours before DLMO for a phase-advance effect [8]. Without knowing the patient's individual DLMO, clinicians are guessing at dosing time.

Normal Salivary Melatonin Ranges and How to Interpret Results

Melatonin's reference ranges are time-dependent, not static. A result of 20 pg/mL at 10:00 PM is normal. The same value at 10:00 AM would be strikingly abnormal. Context matters more than the number alone.

In healthy adults, daytime salivary melatonin sits below 3 pg/mL. Levels begin to rise in the evening, and the DLMO threshold (3 pg/mL) is typically crossed 2 to 3 hours before habitual sleep onset. Peak concentrations of 15 to 50 pg/mL occur between approximately 02:00 and 04:00. By early morning, levels drop back below 3 pg/mL [9]. A large cross-sectional analysis (N=387) published in Chronobiology International found that mean DLMO in healthy adults occurred at 20:48 (8:48 PM) with a standard deviation of 1.4 hours, confirming significant inter-individual variability even among normal sleepers [10].

Age reshapes the curve. Melatonin amplitude decreases with each decade after puberty. A meta-analysis by Bubenik and Konturek (2011) pooling data from 12 studies estimated that adults over 65 produce approximately 50% less nighttime melatonin compared to young adults aged 18-30 [11]. This does not automatically indicate pathology; rather, age-adjusted interpretation is required.

High salivary melatonin. Elevated levels (peak values above 60 pg/mL) are uncommon and may reflect exogenous melatonin supplementation that the patient forgot to disclose, use of beta-blockers (which increase melatonin synthesis via sympathetic pathway modulation), or rarely, a pineal parenchymal tumor. The 2010 Endocrine Society clinical practice guideline on adrenal incidentalomas notes that while pineal tumors are extraordinarily rare, unexplained melatonin elevation warrants imaging [12].

Low salivary melatonin. A blunted amplitude (peak below 10 pg/mL) combined with delayed timing suggests DSWPD with reduced melatonin production. Beta-blocker withdrawal, excessive evening light exposure, and NSAID use can also suppress melatonin. As Dr. Alfred Lewy, a pioneer in melatonin circadian research at Oregon Health & Science University, stated: "A flat melatonin profile in a young patient who avoids light at the right time is biologically significant and should not be dismissed as a lab artifact" [3].

Who Benefits Most: Patient Selection Criteria

Not every patient with a sleep complaint needs this test. Routine primary insomnia, obstructive sleep apnea, and restless legs syndrome are diagnosed through other means. Reserve the salivary melatonin profile for patients where circadian timing is the central question.

Ideal candidates include adolescents and young adults with chronic sleep-onset insomnia unresponsive to standard sleep-hygiene interventions, totally blind patients with cyclically recurring insomnia and daytime somnolence, rotating shift workers whose schedules change every 2 to 4 weeks, patients with traumatic brain injury and new-onset circadian disruption, and patients already taking melatonin who show no response (timing may be wrong rather than the drug being ineffective).

The AASM International Classification of Sleep Disorders, Third Edition (ICSD-3), lists DLMO measurement as a supporting diagnostic tool for all six circadian rhythm sleep-wake disorders [4]. A 2020 position paper from the European Sleep Research Society (ESRS) went further, recommending DLMO as a standard component of the diagnostic workup for DSWPD in specialized sleep centers [13].

Cost is a real barrier. Insurance coverage varies. Most commercial payers classify DLMO testing as investigational, although Medicare has begun covering it under certain CPT codes when ordered by a board-certified sleep specialist with documented clinical necessity. Out-of-pocket costs range from $150 to $400, depending on the reference laboratory and the number of collection points.

How to Prepare Patients for Accurate Results

Collection technique determines data quality. A poorly controlled collection can shift the apparent DLMO by more than an hour, turning a normal result into a false positive for DSWPD.

Light control is non-negotiable. Patients must remain in dim light (<30 lux) for the entire collection window. Overhead fluorescent lights run 300-500 lux. Even a standard tablet screen at full brightness delivers 40-60 lux at arm's length. Provide patients with blue-light-blocking glasses or instruct them to use only dim red-spectrum lighting. A 2019 study in Sleep (N=56) demonstrated that participants who used personal electronic devices during collection had DLMO values delayed by an average of 22 minutes compared to strict dim-light controls [14].

Dietary restrictions. Patients should avoid bananas, tomatoes, walnuts, and other melatonin-containing foods for 12 hours before collection. Caffeine should be avoided for at least 6 hours, as it does not affect melatonin synthesis directly but may alter saliva flow rates and melatonin concentration through dilution effects.

Medication review. Beta-blockers increase melatonin. NSAIDs (particularly ibuprofen and aspirin) suppress it. Fluvoxamine, a potent CYP1A2 inhibitor, can raise melatonin levels 12-fold by blocking hepatic metabolism [15]. Benzodiazepines do not meaningfully alter salivary melatonin. Document all medications and supplements, including over-the-counter melatonin, which must be discontinued for at least 72 hours before testing (some protocols specify 7 days for sustained-release formulations).

Sample handling. Saliva samples must be frozen within 4 hours of collection if not processed immediately. Melatonin in saliva degrades at room temperature, losing roughly 10-15% of immunoreactive melatonin per 24 hours at 25 degrees Celsius [9].

The 2014 consensus statement from the Society for Light Treatment and Biological Rhythms (SLTBR) states: "DLMO assessment without rigorous light control is clinically meaningless; the threshold for environmental interference is lower than most clinicians appreciate" [16].

How to Raise or Lower Melatonin: Clinical Interventions Based on Test Results

The salivary melatonin profile does not exist in a vacuum. Its clinical value depends on what you do with the result.

To advance a delayed DLMO (most common scenario). Administer low-dose exogenous melatonin (0.5-3 mg) approximately 5 hours before the measured DLMO. A 2016 meta-analysis in Sleep Medicine Reviews (9 RCTs, N=358) found that timed melatonin administration advanced DLMO by a mean of 1.5 hours over 4 weeks compared to placebo [17]. Combine this with morning bright light therapy (10,000 lux for 30 minutes) within 2 hours of desired wake time. Evening light restriction beginning 3 hours before target bedtime amplifies the effect.

To delay an advanced DLMO. Evening bright light therapy (2,500-10,000 lux for 1-2 hours) starting at 7:00-8:00 PM can delay the clock. Avoid morning bright light before 8:00 AM. Exogenous melatonin is less useful here because morning administration (needed for a phase delay) tends to cause drowsiness during daytime hours.

To stabilize a free-running rhythm. The FDA-approved melatonin receptor agonist tasimelteon (Hetlioz) is indicated specifically for non-24-hour sleep-wake disorder in totally blind adults. The SET and RESET trials (combined N=104) showed that tasimelteon 20 mg nightly entrained circadian rhythms in 20% of patients versus 3% on placebo, with entrainment confirmed by urinary melatonin metabolite cycling [18].

To boost a blunted amplitude. Address modifiable suppressors first: reduce evening light, discontinue NSAIDs if possible, and optimize sleep regularity. If amplitude remains low, low-dose melatonin (0.5 mg) taken 4-6 hours before DLMO may augment the endogenous signal without causing next-day sedation.

Recheck the salivary melatonin profile 4 to 8 weeks after initiating chronotherapy to confirm the clock has shifted to the target phase.

Limitations and When Not to Order

Salivary melatonin testing is not a screening tool. Do not order it for patients with straightforward primary insomnia, patients whose sleep complaints are better explained by untreated anxiety or depression, or patients who have not first completed a 2-week sleep diary and actigraphy assessment.

The test also has technical limitations. The immunoassay coefficient of variation ranges from 8-15% depending on the kit, meaning small differences between serial collections may reflect assay noise rather than true physiological change [9]. Patients with xerostomia (common in older adults and those on anticholinergics) may produce insufficient saliva volumes, requiring extended collection times that compromise temporal resolution.

Mass spectrometry-based assays (LC-MS/MS) offer greater specificity and lower cross-reactivity than immunoassays but cost more and are available at fewer reference laboratories. For clinical decision-making (phase advance vs. phase delay), the immunoassay is generally sufficient. For research purposes or equivocal cases, LC-MS/MS is preferred.

One systematic review (Benloucif et al., 2008, N=7 studies) concluded that DLMO derived from salivary melatonin and plasma melatonin agreed within 15 minutes in over 90% of cases, supporting the use of salivary testing as a first-line approach [19]. Plasma sampling adds no meaningful diagnostic precision for most patients and introduces the burden of repeated venipuncture.

Order a repeat salivary melatonin profile only when clinical response to chronotherapy is absent or paradoxical, suggesting the initial DLMO result may have been confounded by undisclosed light exposure or medication effects.